HWA 285 (propentofylline) - A new compound for the treatment of both vascular dementia and dementia of the Alzheimer type

Annals of the New York Academy of Sciences

Volumn 777, Issue , 1996, Pages 404-409

  Rother, M ^a   Kittner, B ^a   Rudolphi, K ^a   Roßner M ^a   Labs, K H ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROPENTOFYLLINE;

ALZHEIMER DISEASE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; GASTROINTESTINAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MULTIINFARCT DEMENTIA; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029875457     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb34453.x     Document Type: Conference Paper

References (23)

1. KORCZYN A. D. 1991. The clinical differential diagnosis of dementia: Concept and methodology. Psychiatr. Clin. North Am. 14(2):237-206.
2. BOWEN, D. M. & A. N. DAVISON. 1986. Can the pathophysiology of dementia lead to rational therapy? In Treatment Development Strategies for Alzheimer's Disease. T. Crook, R. Bartus, S. Ferris & S. Gershon, Eds. :36-66. Madison, CT: Mark Powley Associates.
3. BEAL, M. & M. FLINT. 1991. Mechanisms of excitotoxicity in neurologic diseases. FASEB J. 6:3338-3344.
4. FOSTER, A. C. 1990. Physiology and Pathophysiology of Excitatory Amino Acid Neurotransmitter Systems in Relation to Alzheimer's Disease. R. J. Wurtman, et al., Eds. Neurology; 51:97-102. New York: Raven Press.
5. BARTUS, R. T. et al. 1982. The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-417.
6. FRIEDLICH, A. L. & L. L. BUTCHER. 1994. Involvement of free oxygen radicals in amyloidosis: An hypothesis. Neurobiol. Aging; 15:443-455.
7. PARKINSON, F. E., K. A. RUDOLPHI & B. B. FREDHOLM. 1994. HWA 285: A nucleoside transport inhibitor with neuroprotective effects in cerebral ischemia. Gen. Pharmac. 25:1053-1058.
8. +-ATPase activity. Drug Dev. Res. 6:339-344.
9. KADOYA, F., A. MITANI, T. ARAI & K. KATAOKA. 1992. Effects of HWA 285 on hypoxia-hypoglycaemia-induced calcium accumulation in gerbil hippocampal slices. J. Cereb. Blood Flow Metab. 12/2:301-305.
10. DELEO, J., L. TOTH, P. SCHUBERT, K. RUDOLPHI & G. W. KECUTZBERY. 1987. Ischemia-induced neuronal cell death, calcium accumulation, and glial response in the hippocampus of the mongolian gerbil and protection by propentofylline (HWA285). J. Cereb. Blood Flow Metab. 7:745-751.
11. 31P nuclear magnetic resonance spectroscopy. Arzneim.-Forsch./Drug Res. 39:886-889.
12. HIRATA, H., N. OGAWA, K. HABA, M. ASANUMA, H. CHOU & A. MORI. 1992. Effect of HWA 285 on ischaemia-induced loss of muscarinic cholinergic receptor binding in the gerbil hippocampus. Res. Commun. Chem. Pathol. Pharmacol. 75/3:365-368.
13. FUJI, K., M. HIRAMATSU, S. HAYASHI, T. KAMEYAMA & T. NABESHIMA. 1993. Effects of HWA 285, a NGF synthesis stimulator, on alterations in muscarinic cholinergic receptors induced by basal forebrain lesions in rats. Neurosci. Lett. 150:99-102.
14. GOTO, M., N. DEMURA & T. SAKAGUCHI. 1987. Effects of HWA 285 on disorder of learning and memory in rodents. Jpn. J. Pharmacol. 45:373-378.
15. YAMADA, Y., H. NAKAMURA & Y. OKADA. 1994. HWA 285 enhances the formation of long-term potentiation in guinea pig hippocampal slices. Neurosci. Lett. 176:189-192.
16. BANATI, R. B., P. SCHUBERT, G. ROTHE, J. GEHRMANN, K. RUDOLPHI, G. VALET & G. W. KREUTZBERG. 1994. Modulation of intracellular formation of reactive oxygen intermediates in peritoneal macrophages and microglia/brain macrophages by HWA 285. J. Cereb. Blood Flow Metab. 14:145-149.
17. MCRAE, A., K. A. RUDOLPHI & P. SCHUBERT. 1994. HWA 285 depresses amyloid and Alzheimer's CSF microglial antigens after ischemia. Neuroreport 5:1193-1196.
18. SHINODA, I., Y. FURUKAWA & S. FURUKAWA. 1990. Stimulation of nerve growth factor synthesis/secretion by HWA 285 in cultured mouse astroglial cells. Biochem. Pharmacol. 39:1813-1816.
19. NABESHIMA, T., A. NITTA & T. HASEGAWA. 1993. Impairment of learning and memory and the accessory symptoms in aged rats as senile dementia model (3): Oral administration of HWA 285 produces recovery of reduced NGF content in the brain of aged rat. Jpn. J. Psychopharmacol. 13:89-95.
20. MÖLLER, H. J., I. MAURER & B. SALETU. 1994. Placebo-controlled trial of the xanthine derivative HWA 285 in dementia. Pharmacopsychiatry 27/4: 159-165.
21. HUBER, M., B. KITTNER, C. HOYER, G. R. FINK, M. NEVELING & W. D. HEISS. 1993. Effect of HWA 285 on regional cerebral glucose metabolism in acute ischemic stroke. J. Cereb. Blood Flow Metab. 13:526-530.
22. WORKING PARTY ON EFFICACY OF MEDICINAL PRODUCTS, Note for Guidance: Antidementia Medicinal Products. November 1992.
23. KIM, Y. S., D. W. NIBBELINK & J. E. OVERALL. 1993. Factor structure and scoring and the SKT test battery. J. Clin. Psychol. 49:61-71.